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Patients with acute myocardial infarction with ST segment
elevation (STEMI) and multivessel disease (MVD) have a higher
mortality from cardiac causes at 1-year follow-up compared to
patients with one-vessel disease. In multivariate regression
analysis MVD occurred an independent negative prognostic
factor. Multivessel disease is present in 50–60% of all STEMI
patients. In the National registry of cardiovascular interventions
(NRKI, 2005–2007) the incidence of multivessel disease among
more than 16 000 consecutive STEMI patients was 61% (1VD in
38.4%, 2VD in 30.6%, and 3VD in 31%) and MVD was associated
with signiﬁcant increase of 30-day and 1-year mortality
(Fig. 1).
The strategy of complete revascularization in STEMI patients
with MVD remains an important clinical question. Current
guidelines on the management of STEMI recommend infarct-
artery-only PCI in patients with multivessel disease (MVD). The
following general rules were proposed: (1) single-vessel acute
PCI should be the default strategy (to treat only the IRA during
the acute phase of STEMI), (2) acute multivessel PCI can be
justiﬁed only in hemodynamically unstable patients with
multiple truly critical (>90%) lesions, and (3) signiﬁcant lesions
of the non-culprit arteries should be treated by either medically
or staged revascularization procedures – both options are
currently acceptable [1].
Owing to a lack of evidence with respect to the value of
preventive (immediate or staged) multivessel PCI this uncer-
tainty has led to variations in practice, with some cardiologists
performing immediate preventive PCI in spite of the guide-
lines, some delaying preventive PCI until recovery from the
acute episode, and others lifting the procedure to patients with
recurrent symptoms or evidence of ischemia. Several non-
randomized studies, registries or metaanalyses demonstrate
the potential risk of multivessel PCI, but the selection bias was
evident (multivessel PCI performed in small proportion of
more unstable patients with large ischemia, without modern
technologies – thromboaspiration, DES). Conﬂicting to this
evidence, other and more recent studies suggest potential
beneﬁt of multivessel PCI (staged early or immediate).
In a small randomized trial (69 patients), the beneﬁt of
preventive multivessel PCI in patients with acute STEMI
undergoing PCI in the infarct artery was observed in terms of
nonsigniﬁcant reductions in the rates of repeat revasculariza-tion and cardiac death or myocardial infarction [2]. In the other
trial (214 patients), the rate of repeat revascularization was less
frequent in the immediate and staged preventive PCI groups
combined, as compared with the group receiving no preventive
PCI (11% and 33%, respectively), and there was a nonsigniﬁcant
decrease in the rate of cardiac death (5% and 12%, respectively)
[3]. In patients with shock or those resuscitated for cardiac arrest
and multivessel disease immediate multivessel PCI was
associated with signiﬁcant reduction in 6-month mortality
compared with culprit vessel PCI only (survival at 6 months
43.9% vs. 20.4% respectively) [4].
Results of the Randomized Trial of Preventive Angioplasty in
Myocardial Infarction (PRAMI trial) were presented and pub-
lished on September 2013 [5]. Compared with infarct-only
revascularization in patients with acute STEMI undergoing
primary PCI immediate multivessel PCI (complete revasculari-
zation) reduces the risk of cardiovascular events by two-thirds.
The study planned to enroll 600 STEMI patients with multivessel
disease and randomly assigned them to PCI in the infarct-
related artery with or without immediate treatment of other
stenosed vessels. All the other aspects of patient management
were at physician discretion, and subsequent PCI was reserved
only for patients with documented refractory angina. Patients
were enrolled into the study after successful primary PCI of
infarct vessel (2428 STEMI screened, excluded patients with
single vessel disease (1122), left main disease (118) and MVD
unsuitable for PCI (269), 465 randomized: 234 primary plus
preventive PCI, 231 primary PCI only). However, the study was
stopped early when interim results showed an advantage for
the preventive strategy after only 465 patients were treated.
Over a mean follow-up period of 23 months, the combined rate
of cardiac death, nonfatal MI, and refractory angina (primary
endpoint) was 9% in patients who received complete revascu-
larization (n = 234) and 23% in those who had infarct-only PCI
(n = 231). Nonfatal MI and refractory angina were lower with
the preventive strategy, as were the secondary outcome of
repeat revascularization (Table 1). Procedure time, ﬂuoroscopy
dose, and contrast volume were all higher when patients
underwent PCI in all diseased arteries, though complication
rates were similar between the two groups (P = 0.86). The
treatment effect was seen relatively early on. In fact, the curves
(primary endpoint) start to emerge almost immediately, within
days, and the full effect was evident within months and
continued up to 36 months. This may be important because
preventive angioplasty may need to be done immediately to
secure the full beneﬁt.
Fig. 1  – 30-Day and 1-year mortality among consecutive     
STEMI patients treated by primary PCI of culprit vessel only         
(the National registry of cardiovascular interventions,
2005–2007, n = 16 056).
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With improvements in techniques, devices, and medications,
a complete revascularization is reasonable but represents
a departure from current guidelines, particularly when the
secondary sites are not clearly causing ongoing hemodynamic
instability. The potential questions of immediate PCI include:
(1) how relevant is the risk of treating non-infarct-causing
stenosis (related to potentially jeopardize healthy areas of
myocardium when the recovering areas of injured myocardium
are at their weakest), (2) it is unknown whether the risk–beneﬁt
ratio would be preserved if preventive PCI were performed soon
after (staged PCI), rather than during, the initial procedure
(immediate PCI) and (3) how functional assessment (FFR guided
PCI) would change the equation and although it is possible that
this tool would improve lesion selection in acute myocardial
infarction. The risk of overestimating the severity of the lesions
is reported to be high, but it is also plausible that the risk
conferred by the non-infarct lesion is independent of hemody-
namic severity; in such a case, do the beneﬁts extend to
coronary-artery stenoses of less than 50%?) and (4) are the
beneﬁts of preventive PCI applicable to patients with non-STEMI
(such patients tend to be difﬁcult to study because, unlike those
with STEMI (in whom the infarct artery is invariably identiﬁ-
able), there is often uncertainty over which artery is the culprit.
PRAMI challenged the existing dogma that non-culprit
lesions should be not touched during primary PCI. The optimalTable 1 – PRAMI study: immediate multivessel PCI vs. no
additional PCI: clinical outcomes.
HR 95% CI P value
Primary composite 0.35 0.21–0.58 <0.001
Cardiac death 0.34 0.11–1.08 0.07
Nonfatal MI 0.32 0.13–0.75 0.009
Refractory angina  0.35 0.18–0.69 0.002
Repeat revascularization 0.30 0.17–0.56 <0.001timing for non-culprit lesion PCI is debatable. The ﬁnding that
the complete or preventive arm had lower death and MACE than
the culprit-only arm was counter to the three prior major studies
that supported the 2011 PCI guideline class III recommendation
for stenting more than the culprit-only vessel. Criticisms of the
PRAMI study were already mentioned. However, this is one of
the most provocative and potentially important studies that
may lead to a change in the way STEMI interventions have been.
Highlighted questions should be addressed by large Randomized
Comparative Effectiveness Study of Complete vs. Culprit-only
Revascularization Strategies to Treat Multi-vessel Disease
After Primary Percutaneous Coronary Intervention (PCI) for
ST-segment Elevation Myocardial (STEMI) Infarction (COMPLETE
Study), estimated completion during 2019. Until then, multi-
vessel PCI (immediate or staged) may be performed in patients
with STEMI and signiﬁcant lesions suitable to PCI.
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